- $7.00bn
- $6.99bn
- $693.40m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 124.23 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -108.82% | ||
| Return on Equity | n/a | ||
| Operating Margin | -99.67% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 188 | 257.85 | 320.67 | 531.82 | 693.4 | 1,219.11 | 1,521.88 | 62.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The Company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Its product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 26th, 2015
- Public Since
- June 14th, 2024
- No. of Shareholders
- 25
- No. of Employees
- 2,400
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 173,032,863
- Address
- 600 West Chicago Avenue, Suite 510, CHICAGO, 60654
- Web
- https://www.tempus.com/
- Phone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for TEM
Similar to TEM
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Tempus AI share price?
As of Today at 23:37 UTC, shares in Tempus AI are trading at $40.45. This share price information is delayed by 15 minutes.
How has the Tempus AI share price performed this year?
Shares in Tempus AI last closed at $40.45 and the price had moved by over the past 365 days. In terms of relative price strength the Tempus AI share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Tempus AI?
The overall consensus recommendation for Tempus AI is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Tempus AI dividend yield?
Tempus AI does not currently pay a dividend.
Does Tempus AI pay a dividend?
Tempus AI does not currently pay a dividend.
When does Tempus AI next pay dividends?
Tempus AI does not currently pay a dividend.
How do I buy Tempus AI shares?
To buy shares in Tempus AI you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Tempus AI?
As of the previous close price of $40.45, shares in Tempus AI had a market capitalisation of $7.00bn.
Where are Tempus AI shares listed?
Here are the trading details for Tempus AI:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TEM
What kind of share is Tempus AI?
Based on an overall assessment of its quality, value and momentum Tempus AI is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Tempus AI share price forecast for 2025?
The analyst consensus target price for shares in Tempus AI is $62.38. That is 54.22% above the last closing price of $40.45.
Analysts covering Tempus AI currently have a consensus Earnings Per Share (EPS) forecast of -$0.61 for the next financial year.
Find out moreWhat is the trend in the Tempus AI share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Tempus AI. Over the past six months, its share price has underperformed the S&P500 Index by -9.15%.
As of the last closing price of $40.45, shares in Tempus AI were trading -18.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Tempus AI PE Ratio?
The Tempus AI PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $40.45.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Tempus AI?
We do not have data on Tempus AI's directors